Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 54
Filter
1.
Ukr Biochem J ; 89(1): 59-70, 2017.
Article in English | MEDLINE | ID: mdl-29236390

ABSTRACT

To verify the idea that extracellular free oligosaccharides might be able to reflect the functional status of the endoplasmic reticulum (ER) and lysosomal-endosomal system, HPLC-profiles of serum-derived free oligosaccharides (FOS) in human healthy aging, acute myeloproliferative neoplasms, and cardiovascular pathologies were compared with intracellular glycans. After plasma deproteinization and FOS purification the oligosaccharides were labelled with anthranilic acid, separated into the neutral and charged with QAE Sephadex (Q25-120) chromatography and analysed using high-performance liquid chromatography (HPLC). The charged FOS were digested with a sialidase and compared with free oligosaccharides from transferrin for structural decoding. HPLC-profiles of serum-derived FOS revealed mild delay of the dolichol phosphate cycle in ER, moderate intensification of ER-associated degradation (ERAD) and degradation in endosomal-lysosomal system with aging; an inhibition of the dolichol phosphate cycle, intensification of ERAD and increasing of lysosomal exocytosis in acute myeloproliferative neoplasms; intensification of ERAD and glycocojugate degradation with endosomal-lysosomal system in cardiovascular diseases. As serum free oligosaccharides are able to reflect specifically perturbations in ER and endosomal-lysosomal system under wide range of stressors they can serve as extracellular markers of functionality of these organelles.


Subject(s)
Cardiovascular Diseases/blood , Dolichol Phosphates/blood , Endoplasmic Reticulum-Associated Degradation , Glycoconjugates/blood , Healthy Aging/blood , Myeloproliferative Disorders/blood , Oligosaccharides/blood , Biomarkers/blood , Biomarkers/chemistry , Carbohydrate Sequence , Cardiovascular Diseases/diagnosis , Case-Control Studies , Endoplasmic Reticulum/metabolism , Endosomes/metabolism , Glycosylation , Humans , Lysosomes/metabolism , Myeloproliferative Disorders/diagnosis , Oligosaccharides/chemistry , Staining and Labeling/methods , ortho-Aminobenzoates/chemistry
2.
Org Biomol Chem ; 14(44): 10371-10385, 2016 Nov 08.
Article in English | MEDLINE | ID: mdl-27735004

ABSTRACT

This paper explores the computer modelling aided design and synthesis of ß-N-acetylhexosaminidase inhibitors along with their applicability to human disease treatment through biological evaluation in both an enzymatic and cellular setting. We investigated the importance of individual stereocenters, variations in structure-activity relationships along with factors influencing cell penetration. To achieve these goals we modified nitrogen heterocycles in terms of ring size, side chains present and ring nitrogen derivatization. By reducing the inhibitor interactions with the active site down to the essentials we were able to determine that besides the established 2S,3R trans-relationship, the presence and stereochemistry of the CH2OH side chain is of crucial importance for activity. In terms of cellular penetration, N-butyl side chains favour cellar uptake, while hydroxy- and carboxy-group bearing sidechains on the ring nitrogen retarded cellular penetration. Furthermore we show an early proof of principle study that ß-N-acetylhexosaminidase inhibitors can be applicable to use in a potential anti-invasive anti-cancer strategy.

3.
Org Biomol Chem ; 12(44): 8977-96, 2014 Nov 28.
Article in English | MEDLINE | ID: mdl-25277226

ABSTRACT

The glycosidase inhibitory properties of synthetic C-alkyl and N-alkyl six-membered iminosugars have been extensively studied leading to therapeutic candidates. The related seven-membered iminocyclitols have been less examined despite the report of promising structures. Using an in house ring enlargement/C-alkylation as well as cross-metathesis methodologies as the key steps, we have undertaken the synthesis and biological evaluation of a library of fourteen 2C- and eight N-alkyl tetrahydroxylated azepanes starting from an easily available glucopyranose-derived azidolactol. Four, six, nine and twelve carbon atom alkyl chains have been introduced. The study of two distinct D-gluco and L-ido stereochemistries for the tetrol pattern as well as R and S configurations for the C-2 carbon bearing the C-alkyl chain is reported. We observed that C-alkylation of the L-ido tetrahydroxylated azepane converts it from an α-L-fucosidase to a ß-glucosidase and ß-galactosidase inhibitor while N-alkylation of the D-gluco iminosugar significantly improves its inhibition profile leading to potent ß-glucosidase, ß-galactosidase, α-L-rhamnosidase and ß-glucuronidase inhibitors whatever the stereochemistry of the alkyl chain. Interestingly, the N-alkyl chain length usually parallels the azepane inhibitor potency as exemplified by the identification of a potent glucocerebrosidase inhibitor (Ki 1 µM) bearing a twelve carbon atom chain. Additionally, several C-alkyl azepanes demonstrated promising F508del-CFTR correction unlike the parent tetrahydroxyazepanes. None of the C-alkyl and N-alkyl azepanes did inhibit ER α-glucosidases I or II.


Subject(s)
Cystic Fibrosis Transmembrane Conductance Regulator/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Glucosylceramidase/antagonists & inhibitors , Imino Sugars/pharmacology , Alkylation , Crystallography, X-Ray , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis Transmembrane Conductance Regulator/metabolism , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , Glucosylceramidase/metabolism , Humans , Imino Sugars/chemical synthesis , Imino Sugars/chemistry , Models, Molecular , Molecular Conformation , Structure-Activity Relationship
4.
Ukr Biochem J ; 86(6): 5-17, 2014.
Article in English | MEDLINE | ID: mdl-25816601

ABSTRACT

Metabolism of glycoproteins and glycolipids is accompanied by the appearance of unbound structural analogues of the carbohydrate portion of glycoconjugates or so called free oligosaccharides. There are their several sources inside the cell: 1) multistep pathways of N-glycosylation, 2) the cell quality control and ER-associated degradation of misglycosylated and/or misfolded glycoproteins, 3) lysosomal degradation of mature glycoconjugates. In this review the information about the ways of free oligosaccharides appearance in different cell compartments and details of their structures depending on the source is summarized. In addition, extracellular free oligosaccharides, their structures and changes under normal and pathological conditions are discussed.


Subject(s)
Eukaryotic Cells/metabolism , Glycoconjugates/metabolism , Glycoproteins/metabolism , Lysosomal Storage Diseases/metabolism , Lysosomes/metabolism , Oligosaccharides/metabolism , Carbohydrate Sequence , Endoplasmic Reticulum/metabolism , Endoplasmic Reticulum/pathology , Endoplasmic Reticulum-Associated Degradation , Eukaryotic Cells/pathology , Glycoconjugates/chemistry , Glycoproteins/chemistry , Glycosylation , Humans , Lysosomal Storage Diseases/pathology , Lysosomes/pathology , Molecular Sequence Data , Oligosaccharides/chemistry , Protein Folding
5.
Lupus ; 22(10): 1070-6, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23864039

ABSTRACT

We describe a female patient with systemic lupus erythematosus (SLE) also diagnosed with Fabry's disease and anti-phospholipid antibody syndrome (APS). SLE and Fabry's disease are both systemic diseases with variable clinical presentations. Recent studies have shown a relatively high incidence of late onset Fabry's disease in female heterozygous individuals, suggesting that this condition could be under-diagnosed. We discuss a possible association between SLE and Fabry's disease and consider the role of lipid abnormalities in the pathogenesis of SLE.


Subject(s)
Antiphospholipid Syndrome/complications , Fabry Disease/complications , Heart Failure/etiology , Lupus Erythematosus, Systemic/complications , Adult , Diagnosis, Differential , Female , Humans , Lupus Erythematosus, Systemic/etiology
6.
Bioorg Med Chem ; 21(16): 4831-8, 2013 Aug 15.
Article in English | MEDLINE | ID: mdl-23582447

ABSTRACT

Deoxynojirimycin (DNJ) based imino sugars display antiviral activity in the tissue culture surrogate model of Hepatitis C (HCV), bovine viral diarrhoea virus (BVDV), mediated by inhibition of ER α-glucosidases. Here, the antiviral activities of neoglycoconjugates derived from deoxynojirimycin, and a novel compound derived from deoxygalactonojirimycin, by click chemistry with functionalised adamantanes are presented. Their antiviral potency, in terms of both viral infectivity and virion secretion, with respect to their effect on α-glucosidase inhibition, are reported. The distinct correlation between the ability of long alkyl chain derivatives to inhibit ER α-glucosidases and their anti-viral effect is demonstrated. Increasing alkyl linker length between DNJ and triazole groups increases α-glucosidase inhibition and reduces the production of viral progeny RNA and the maturation of the envelope polypeptide. Disruption to viral glycoprotein processing, with increased glucosylation on BVDV E2 species, is representative of α-glucosidase inhibition, whilst derivatives with longer alkyl linkers also show a further decrease in infectivity of secreted virions, an effect proposed to be distinct from α-glucosidase inhibition.


Subject(s)
Antiviral Agents/chemistry , Enzyme Inhibitors/chemistry , Glycoside Hydrolase Inhibitors , Imino Sugars/chemistry , 1-Deoxynojirimycin/chemistry , Animals , Antiviral Agents/chemical synthesis , Antiviral Agents/pharmacology , Cattle , Cell Survival/drug effects , Click Chemistry , Diarrhea Viruses, Bovine Viral/metabolism , Dogs , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Glucosamine/analogs & derivatives , Glucosamine/chemistry , Glycosylation , Hepacivirus/metabolism , Imino Sugars/chemical synthesis , Imino Sugars/pharmacology , Madin Darby Canine Kidney Cells , Viral Envelope Proteins/metabolism , Virus Replication/drug effects , alpha-Glucosidases/metabolism
7.
Diabetes Obes Metab ; 10(2): 159-66, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18190430

ABSTRACT

AIM: To determine the mechanism of weight loss caused by high doses of N-butyldeoxynojirimycin (NB-DNJ) in healthy lean and leptin-deficient obese (ob/ob) mice. METHODS: Healthy lean and obese mice were treated with NB-DNJ by the following methods: admixed with their diet, delivered by subcutaneously implanted mini-pumps or by intraperitoneal or intracerebroventricular (ICV) injection. Daily changes in body weight and food intake were recorded during the experimental period. The effect of NB-DNJ treatment on subcutaneous adipose tissue and on epididymal fat pads was measured. RESULTS: Lean mice treated with NB-DNJ, admixed with their diet, lost weight in the form of adipose tissue. This resulted in a 40% reduction in skin thickness (control, 358 +/- 11 microm; NB-DNJ treated 203 +/- 6 microm) and a reduction in epididymal fat pad weights after 5 weeks of treatment at 2400 mg/kg/day (control, 0.0154 +/- 0.001; NB-DNJ treated, 0.0026 +/- 0.0005 as ratios of fat pad weight to total body weight). Following the depletion of adipose tissue mass, the mice grew normally and did not have any reduction in lean mass. Obese mice treated with NB-DNJ also lost weight or gained weight at a greatly reduced rate compared with non-treated controls. Body weights at 6 months of age were: lean control, 29.10 +/- 1.15 g; lean NB-DNJ treated, 22.73 +/- 0.29 g; obese control, 63.25 +/- 1.5 g; obese NB-DNJ treated from 5 weeks of age, 35.30 +/- 1.68 g; obese NB-DNJ treated from 12 weeks of age, 38.84 +/- 1.26 g. Both the lean and obese groups of mice treated with NB-DNJ ate up to 30% less than untreated controls. Daily food intake (powder diet) were: lean control, 4.15 +/- 0.54 g; obese control, 4.14 +/- 0.2 g; lean NB-DNJ treated 2.9 +/- 0.37 g; obese NB-DNJ treated, 2.88 +/- 0.47 g. Mice treated with the N-substituted galactose imino sugar analogue, N-butyldeoxygalactonojirimycin (NB-DGJ) did not lose weight. Mice experienced similar weight loss or lack of weight gain when fed a restricted diet that mimics the drug-induced level of food consumption. Delivery of 2 nmol NB-DNJ by ICV injection into lean mice also caused similar reductions in food intake. Food intake: saline vehicle, 4.30 +/- 0.12 g; NB-DNJ, 3.37 +/- 0.19 g; NB-DGJ, 4.03 +/- 0.16 g; 2-deoxyglucose, 4.7 +/- 0.15 g. CONCLUSION: NB-DNJ causes weight loss as a result of reduced food consumption due to central appetite suppression.


Subject(s)
1-Deoxynojirimycin/analogs & derivatives , Adipose Tissue/drug effects , Appetite Regulation/drug effects , Enzyme Inhibitors/adverse effects , Obesity/metabolism , Weight Loss/drug effects , 1-Deoxynojirimycin/administration & dosage , 1-Deoxynojirimycin/adverse effects , Animals , Leptin/deficiency , Mice , Mice, Obese
8.
J Inherit Metab Dis ; 30(1): 79-87, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17189993

ABSTRACT

OBJECTIVE: Fabry disease results from alpha-gala-ctosidase A deficiency and is characterized by the lysosomal accumulation of globotriaosylceramide. Globotriaosylceramide storage predominantly affects endothelial cells, altering vascular wall morphology and vasomotor function. Our objective was to investigate aortic globotriaosylceramide levels, morphology and function in a mouse model of Fabry disease, and the effect of substrate reduction therapy, using the glycosphingolipid biosynthesis inhibitor N-butyldeoxynojirimycin. METHODS AND RESULTS: Mice used were C57BL/6J and alpha-galactosidase A knockout (Fabry). We show progressive accumulation of aortic globotriaosylceramide throughout the lifespan of untreated Fabry mice (55-fold elevation at 2 months increasing to 187-fold by 19 months), localized to endothelial and vascular smooth-muscle cells; there was no effect on vascular wall morphology in young Fabry mice. In old mice, storage resulted in intimal thickening. Endothelial function declined with age in Fabry mouse aorta. Aortae from N-butyldeoxynojirimycin-treated Fabry mice at 19 months of age had reduced endothelial globotriaosylceramide storage, fewer morphological abnormalities and less severe vasomotor dysfunction compared with untreated littermates. CONCLUSION: We provide evidence of a novel vascular phenotype in the Fabry mouse that has relevance to vascular disease in Fabry patients. N-Butyldeoxynojirimycin treatment partially prevented the phenotype in the Fabry mouse by reducing endothelial globotriaosylceramide storage.


Subject(s)
1-Deoxynojirimycin/analogs & derivatives , Aorta/drug effects , Aorta/pathology , Enzyme Inhibitors/therapeutic use , Fabry Disease/drug therapy , 1-Deoxynojirimycin/therapeutic use , Animals , Aorta/metabolism , Aorta/ultrastructure , Disease Models, Animal , Female , Humans , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Microscopy, Electron , Phenotype , alpha-Galactosidase/genetics
9.
J Inherit Metab Dis ; 27(6): 757-66, 2004.
Article in English | MEDLINE | ID: mdl-15505381

ABSTRACT

It has been shown that treatment with miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) improves key clinical features of type I Gaucher disease after 1 year of treatment. This study reports longer-term efficacy and safety data. Patients who had completed 12 months of treatment with open-label miglustat (100-300 mg three times daily) were enrolled to continue with therapy in an extension study. Data are presented up to month 36. Liver and spleen volumes measured by CT or MRI were scheduled every 6 months. Biochemical and haematological parameters, including chitotriosidase activity (a sensitive marker of Gaucher disease activity) were monitored every 3 months. Safety data were also collected every 3 months. Eighteen of 22 eligible patients at four centres entered the extension phase and 14 of these completed 36 months of treatment with miglustat. After 36 months, there were statistically significant improvements in all major efficacy endpoints. Liver and spleen organ volumes were reduced by 18% and 30%, respectively. In patients whose haemoglobin value had been below 11.5 g/dl at baseline, mean haemoglobin increased progressively from baseline by 0.55 g/dl at month 12 (NS), 1.28 g/dl at month 24 (p =0.007), and 1.30 g/dl at month 36 (p =0.013). The mean platelet count at month 36 increased from baseline by 22 x 10(9)/L. No new cases of peripheral neuropathy occurred since previously reported. Diarrhoea and weight loss, which were frequently reported during the initial 12-month study, decreased in magnitude and prevalence during the second and third years. Patients treated with miglustat for 3 years show significant improvements in organ volumes and haematological parameters. In conclusion, miglustat was increasingly effective over time and showed acceptable tolerability in patients who continued with treatment for 3 years.


Subject(s)
1-Deoxynojirimycin/analogs & derivatives , 1-Deoxynojirimycin/therapeutic use , Enzyme Inhibitors/therapeutic use , Gaucher Disease/drug therapy , 1-Deoxynojirimycin/adverse effects , Administration, Oral , Electromyography , Enzyme Inhibitors/adverse effects , Gaucher Disease/pathology , Gaucher Disease/physiopathology , Hemoglobins/metabolism , Hexosaminidases/blood , Humans , Liver/pathology , Magnetic Resonance Imaging , Neural Conduction/physiology , Platelet Count , Spleen/pathology , Tomography, X-Ray Computed
10.
Brain ; 126(Pt 4): 974-87, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12615653

ABSTRACT

Mouse models of the GM2 gangliosidoses [Tay-Sachs, late onset Tay-Sachs (LOTS), Sandhoff] and GM1 gangliosidosis have been studied to determine whether there is a common neuro-inflammatory component to these disorders. During the disease course, we have: (i) examined the expression of a number of inflammatory markers in the CNS, including MHC class II, CD68, CD11b (CR3), 7/4, F4/80, nitrotyrosine, CD4 and CD8; (ii) profiled cytokine production [tumour necrosis factor alpha (TNF alpha), transforming growth factor (TGF beta 1) and interleukin 1 beta (IL1 beta)]; and (iii) studied blood-brain barrier (BBB) integrity. The kinetics of apoptosis and the expression of Fas and TNF-R1 were also assessed. In all symptomatic mouse models, a progressive increase in local microglial activation/expansion and infiltration of inflammatory cells was noted. Altered BBB permeability was evident in Sandhoff and GM1 mice, but absent in LOTS mice. Progressive CNS inflammation coincided with the onset of clinical signs in these mouse models. Substrate reduction therapy in the Sandhoff mouse model slowed the rate of accumulation of glycosphingolipids in the CNS, thus delaying the onset of the inflammatory process and disease pathogenesis. These data suggest that inflammation may play an important role in the pathogenesis of the gangliosidoses.


Subject(s)
Antigens, CD/metabolism , Cytokines/metabolism , Gangliosidoses/etiology , Genes, MHC Class II/physiology , 1-Deoxynojirimycin/analogs & derivatives , 1-Deoxynojirimycin/therapeutic use , Animals , Apoptosis , Biomarkers/analysis , Blood-Brain Barrier , Enzyme Inhibitors/therapeutic use , Gangliosidoses/drug therapy , Gangliosidoses/pathology , Gangliosidoses, GM2/drug therapy , Gangliosidoses, GM2/etiology , Gangliosidoses, GM2/pathology , Gangliosidosis, GM1/drug therapy , Gangliosidosis, GM1/etiology , Gangliosidosis, GM1/pathology , Immunohistochemistry , Inflammation/pathology , Mice , Sandhoff Disease/drug therapy , Sandhoff Disease/etiology , Sandhoff Disease/pathology , Tay-Sachs Disease/drug therapy , Tay-Sachs Disease/etiology , Tay-Sachs Disease/pathology
11.
Adv Exp Med Biol ; 535: 219-26, 2003.
Article in English | MEDLINE | ID: mdl-14714898

ABSTRACT

Glycosphingolipid lysosomal storage diseases are a small but challenging group of human disorders to treat. Although these appear to be monogenic disorders where the catalytic activity of enzymes in glycosphingolipid catabolism is impaired, the presentation and severity of disease is heterogeneous. Treatment is often restricted to palliative care, but in some disorders enzyme replacement does offer a significant clinical improvement of disease severity. An alternative therapeutic approach termed "substrate deprivation" or "substrate reduction therapy" (SRT) aims to reduce cellular glycosphingolipid biosynthesis to match the impairment in catalytic activity seen in lysosomal storage disorders. N-Alkylated imino sugars are nitrogen containing polyhydroxylated heterocycles that have inhibitory activity against the first enzyme in the pathway for glucosylating sphingolipid in eukaryotic cells, ceramide-specific glucosyltransferase. The use of N-alkylated imino sugars to establish SRT as an alternative therapeutic strategy is described in cell culture and gene knockout mouse disease models. One imino sugar, N-butyl-DNJ (NB-DNJ) has been used in clinical trials for type 1 Gaucher disease and has shown to be an effective and safe therapy for this disorder. The results of these trials and the prospects of improvement to the design of imino sugar compounds for treating Gaucher and other glycosphingolipid lysosomal storage disorders will be discussed.


Subject(s)
1-Deoxynojirimycin/analogs & derivatives , Glycosphingolipids/metabolism , Lysosomal Storage Diseases/drug therapy , 1-Deoxynojirimycin/pharmacology , Animals , Disease Models, Animal , Drug Therapy, Combination , Enzyme Inhibitors/pharmacology , Gaucher Disease/drug therapy , Humans , In Vitro Techniques , Lysosomal Storage Diseases/metabolism , Mice
12.
Neuropathol Appl Neurobiol ; 28(5): 343-57, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12366816

ABSTRACT

Paediatric neurodegenerative diseases are frequently caused by inborn errors in glycosphingolipid (GSL) catabolism and are collectively termed the glycosphingolipidoses. GSL catabolism occurs in the lysosome and a defect in an enzyme involved in GSL degradation leads to the lysosomal storage of its substrate(s). GSLs are abundantly expressed in the central nervous system (CNS) and the disorders frequently have a progressive neurodegenerative course. Our understanding of pathogenesis in these diseases is incomplete and currently few options exist for therapy. In this review we discuss how mouse models of these disorders are providing insights into pathogenesis and also leading to progress in evaluating experimental therapies.


Subject(s)
Glucosylceramides/metabolism , Glycosphingolipids/metabolism , Lysosomal Storage Diseases/etiology , Lysosomal Storage Diseases/therapy , Lysosomes/metabolism , 1-Deoxynojirimycin/administration & dosage , 1-Deoxynojirimycin/analogs & derivatives , Animals , Bone Marrow Transplantation , Chemotherapy, Adjuvant , Disease Models, Animal , G(M2) Ganglioside/metabolism , Gangliosides/metabolism , Glucosyltransferases/antagonists & inhibitors , Glucosyltransferases/metabolism , Humans , Lysosomal Storage Diseases/metabolism , Lysosomal Storage Diseases/pathology , Mice , Models, Biological , Models, Chemical , Morpholines/administration & dosage , Sandhoff Disease/etiology , Sandhoff Disease/metabolism , Sandhoff Disease/pathology , Sandhoff Disease/therapy , Tay-Sachs Disease/etiology , Tay-Sachs Disease/metabolism , Tay-Sachs Disease/pathology , Tay-Sachs Disease/therapy , Treatment Outcome
13.
Anal Biochem ; 298(2): 207-17, 2001 Nov 15.
Article in English | MEDLINE | ID: mdl-11700975

ABSTRACT

The functional importance of glycolipids has emphasized the need for more sensitive methods of detection, characterization, and quantification than has often been possible using traditional thin-layer chromatographic techniques. We describe the use of ceramide glycanase and HPLC to identify and quantify gangliosides in which the carbohydrate is in Glcbeta1--> linkage with ceramide. Detection of released carbohydrate was by fluorescent labeling with 2-aminobenzamide at the reducing terminal prior to HPLC analysis. Under the conditions described, ceramide glycanase hydrolyzed all of the common gangliosides studied, offering a broad spectrum of specificity. Release and detection of carbohydrate were linear over a wide range (over two orders of magnitude) of micromolar glycolipid substrate concentrations. Use of an N-linked glycan as an internal standard allowed accurate quantification and a recovery of 93% was achieved. The method additionally maintained the sensitivity (chromatographic peaks containing 1 pmol were readily detected from tissue samples) and comparable resolution to related assays. This was shown by the separation, not only of isomeric carbohydrates from the "a" and "b" series, but also of ganglioside carbohydrate differing only by the presence of either N-acetyl- or N-glycolylneuraminic acid. Application of the method to neutral glycosphingolipids and to tissue samples, including 10-microl quantities of plasma, is illustrated. Glycan structures were confirmed by exoglycosidase digestion and/or matrix-assisted laser desorption/ionization mass spectrometry.


Subject(s)
Chromatography, High Pressure Liquid/methods , Fluorescent Dyes , Glycoside Hydrolases/metabolism , Oligosaccharides/chemistry , ortho-Aminobenzoates , Aminopyridines , Animals , CHO Cells , Carbohydrate Sequence , Chromatography, Thin Layer , Cricetinae , Female , Glycolipids/blood , Glycosphingolipids/metabolism , Humans , Liver/metabolism , Mice , Molecular Sequence Data , Oligosaccharides/isolation & purification , Sarcoma/metabolism , Sensitivity and Specificity , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Uterine Neoplasms/metabolism
14.
J Virol ; 75(19): 8987-98, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11533162

ABSTRACT

The glucose-derived iminosugar derivatives N-butyl- and N-nonyl-deoxynojirimycin (DNJ) have an antiviral effect against a broad spectrum of viruses including Bovine viral diarrhea virus (BVDV). For BVDV, this effect has been attributed to the reduction of viral secretion due to an impairment of viral morphogenesis caused by the ability of DNJ-based iminosugar derivatives to inhibit ER alpha-glucosidases (N. Zitzmann, A. S. Mehta, S. Carrouée, T. D. Butters, F. M. Platt, J. McCauley, B. S. Blumberg, R. A. Dwek, and T. M. Block, Proc. Natl. Acad. Sci. USA 96:11878-11882, 1999). Here we present the antiviral features of newly designed DNJ derivatives and report for the first time the antiviral activity of long-alkyl-chain derivatives of deoxygalactonojirimycin (DGJ), a class of iminosugars derived from galactose which does not inhibit endoplasmic reticulum (ER) alpha-glucosidases. We demonstrate the lack of correlation between the ability of long-alkyl-chain DNJ derivatives to inhibit ER alpha-glucosidases and their antiviral effect, ruling out ER alpha-glucosidase inhibition as the sole mechanism responsible. Using short- and long-alkyl-chain DNJ and DGJ derivatives, we investigated the mechanisms of action of these drugs. First, we excluded their potential action at the level of the replication, protein synthesis, and protein processing. Second, we demonstrated that DNJ derivatives cause both a reduction in viral secretion and a reduction in the infectivity of newly released viral particles. Long-alkyl-chain DGJ derivatives exert their antiviral effect solely via the production of viral particles with reduced infectivity. We demonstrate that long-alkyl-chain DNJ and DGJ derivatives induce an increase in the quantity of E2-E2 dimers accumulated within the ER. The subsequent enrichment of these homodimers in secreted virus particles correlates with their reduced infectivity.


Subject(s)
Diarrhea Viruses, Bovine Viral/drug effects , Enzyme Inhibitors/pharmacology , Glucosamine/analogs & derivatives , Glucosamine/pharmacology , 1-Deoxynojirimycin/analogs & derivatives , Animals , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Bovine Virus Diarrhea-Mucosal Disease/drug therapy , Cattle , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/therapeutic use , Glucosamine/chemistry , Glucosamine/therapeutic use , Virus Replication/drug effects
15.
J Inherit Metab Dis ; 24(2): 275-90, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11405346

ABSTRACT

The glycosphingolipid (GSL) lysosomal storage diseases are caused by mutations in the genes encoding the glycohydrolases that catabolize GSLs within lysosomes. In these diseases the substrate for the defective enzyme accumulates in the lysosome and the stored GSL leads to cellular dysfunction and disease. The diseases frequently have a progressive neurodegenerative course. The therapeutic options for treating these diseases are relatively limited, and for the majority there are no effective therapies. The problem is further compounded by difficulties in delivering therapeutic agents to the brain. Most research effort to date has focused on strategies for augmenting enzyme levels to compensate for the underlying defect. These include bone marrow transplantation (BMT), enzyme replacement and gene therapy. An alternative strategy that we have been exploring is substrate deprivation. This approach aims to balance the rate of GSL synthesis with the impaired rate of GSL breakdown. The imino sugar N-butyldeoxynojirimycin (NB-DNJ) inhibits the first step in GSL biosynthesis and has been used to evaluate this approach. Studies in an asymptomatic mouse model of Tay-Sachs disease have shown that substrate deprivation prevents GSL storage in the CNS. In a severe neurodegenerative mouse model of Sandhoff disease, substrate deprivation delayed the onset of symptoms and disease progression and significantly increased life expectancy. Combining NB-DNJ and BMT was found to be synergistic in the Sandhoff mouse model. A clinical trial in type I Gaucher disease has been undertaken and has shown beneficial effects. Efficacy was demonstrated on the basis of significant decreases in liver and spleen volumes, gradual but significant improvement in haematological parameters and disease activity markers, together with diminished GSL biosynthesis and storage as determined by independent biochemical assays. Further trials in type I Gaucher disease are in progress; studies are planned in patients with GSL storage in the CNS.


Subject(s)
Glycolipids/metabolism , Glycoside Hydrolases/antagonists & inhibitors , Lysosomal Storage Diseases/therapy , Animals , Glycoside Hydrolases/metabolism , Glycosphingolipids/metabolism , Humans , Lysosomal Storage Diseases/enzymology
16.
Blood ; 97(1): 327-9, 2001 Jan 01.
Article in English | MEDLINE | ID: mdl-11133779

ABSTRACT

Sandhoff disease is a lysosomal storage disorder characterized by G(M2) ganglioside accumulation in the central nervous system (CNS) and periphery. It results from mutations in the HEXB gene, causing a deficiency in beta-hexosaminidase. Bone marrow transplantation (BMT), which augments enzyme levels, and substrate deprivation (using the glycosphingolipid biosynthesis inhibitor N-butyldeoxynojirimycin [NB-DNJ]) independently have been shown to extend life expectancy in a mouse model of Sandhoff disease. The efficacy of combining these 2 therapies was evaluated. Sandhoff disease mice treated with BMT and NB-DNJ survived significantly longer than those treated with BMT or NB-DNJ alone. When the mice were subdivided into 2 groups on the basis of their donor bone marrow-derived CNS enzyme levels, the high enzyme group exhibited a greater degree of synergy (25%) than the group as a whole (13%). Combination therapy may therefore be the strategy of choice for treating the infantile onset disease variants.


Subject(s)
1-Deoxynojirimycin/analogs & derivatives , 1-Deoxynojirimycin/therapeutic use , Bone Marrow Transplantation , Sandhoff Disease/therapy , Animals , Brain/metabolism , Diagnostic Techniques, Neurological , Disease Models, Animal , Enzyme Inhibitors/therapeutic use , Glycosphingolipids/metabolism , Hexosaminidase B , Mice , Spinal Cord/metabolism , Survival Rate , beta-N-Acetylhexosaminidases/metabolism
17.
Anal Biochem ; 284(1): 136-42, 2000 Aug 15.
Article in English | MEDLINE | ID: mdl-10933866

ABSTRACT

The use of imino sugars for the potential treatment of lysosomal glycolipid storage diseases and hepatitis virus infections requires accurate, quantitative measurement of these compounds in biological samples. We demonstrate here the versatility of cation-exchange chromatography and pulsed amperometric detection of a range of compounds that differ in both isometric structure and N-alkyl chain length. Although column retention appears dependent upon residual charge on the imine function, successful isocratic separation can be achieved by secondary hydrophobic interactions. A series of N-alkylated deoxynojirimycin compounds containing C(1-10) alkyl chains are readily separated and detected by pulsed amperometry after cation suppression. Using experimentally derived response factors for imino sugars and measurement of peak areas we have developed a reliable method for quantitatively determining concentrations in solution. A rapid protocol for the removal of protein and contaminants in biological samples is described. This has allowed the successful measurement of imino sugars in animal tissues and will be useful for understanding the factors involved in compound bioavailability and in the design of novel therapeutics.


Subject(s)
Carbohydrates/analysis , Carbohydrates/isolation & purification , Chromatography, Ion Exchange/methods , 1-Deoxynojirimycin/analogs & derivatives , 1-Deoxynojirimycin/isolation & purification , Animals , Brain/metabolism , Carbohydrates/blood , Cations , Electrochemistry , Liver/metabolism , Lysosomal Storage Diseases/blood , Mice , Mice, Inbred C57BL , Models, Chemical , Time Factors
18.
Biochem Pharmacol ; 59(7): 821-9, 2000 Apr 01.
Article in English | MEDLINE | ID: mdl-10718340

ABSTRACT

N-Butyldeoxynojirimycin (NB-DNJ) inhibits the ceramide glucosyltransferase which catalyses the first step in glycosphingolipid (GSL) biosynthesis. It has the potential to be used for the treatment of the GSL lysosomal storage diseases and is currently in clinical trials for the treatment of type 1 Gaucher's disease. However, NB-DNJ is also a potent inhibitor of other enzymes, including alpha-glucosidase I and II, which could potentially cause side effects in patients receiving life-long therapy. Wetherefore evaluated a potentially more selective GSL biosynthesis inhibitor, N-butyldeoxygalactonojirimycin (NB-DGJ), in vitro and in vivo. The distribution and degree of GSL depletion in the liver of mice treated with NB-DGJ or NB-DNJ were equivalent. Mice treated with NB-DGJ had normal body weights and lymphoid organ sizes, whereas NB-DNJ-treated mice showed weight loss and partial lymphoid organ shrinkage. NB-DNJ inhibited glycogen catabolism in the liver, whereas NB-DGJ did not. NB-DNJ was also a potent inhibitor of sucrase and maltase in vitro but not of lactase, while NB-DGJ inhibited lactase but not sucrase or maltase. NB-DGJ is therefore more selective than NB-DNJ, and deserves to be evaluated for human therapy.


Subject(s)
1-Deoxynojirimycin/analogs & derivatives , Enzyme Inhibitors/pharmacology , Glycosphingolipids/biosynthesis , Liver/metabolism , 1-Deoxynojirimycin/adverse effects , 1-Deoxynojirimycin/pharmacokinetics , 1-Deoxynojirimycin/pharmacology , Animals , Carbon Radioisotopes , Cell Division/drug effects , Disaccharidases/antagonists & inhibitors , Enzyme Inhibitors/adverse effects , Enzyme Inhibitors/pharmacokinetics , Female , Glycogen/metabolism , Humans , Lymphocytes/drug effects , Mice , Mice, Inbred C57BL , Tissue Distribution
20.
Expert Rev Mol Med ; 2(1): 1-17, 2000 Feb 01.
Article in English | MEDLINE | ID: mdl-14585134

ABSTRACT

The glycosphingolipid (GSL) lysosomal storage diseases are a family of human metabolic diseases that, in their severest forms, cause death in early infancy, as a result of progressive neurodegeneration. They are caused by mutations in the genes encoding the glycohydrolases or the activator proteins that catabolise GSLs within lysosomes. In these diseases the GSL substrate of the defective enzyme accumulates in the lysosome, where it is stored and leads to cellular dysfunction and disease. The therapeutic options for treating these diseases are relatively limited; in fact, there are currently no available therapies for most of these disorders. The problem is further compounded by difficulties in delivering therapeutic agents to the central nervous system, which is where the pathology is frequently manifested. To date, research effort has mainly focused on strategies for augmenting enzyme concentrations to compensate for the underlying defect. These strategies include bone-marrow transplantation, enzyme-replacement therapy and gene therapy. Our group has been exploring the alternative strategy of substrate deprivation. This approach aims to balance the rate of GSL synthesis with the impaired rate of GSL breakdown. Studies using an asymptomatic mouse model of Tay-Sachs disease have shown that substrate deprivation prevents GSL storage. In a severe neurodegenerative mouse model of Sandhoff disease, substrate deprivation delayed the onset of symptoms and disease progression, and significantly increased life expectancy. The implications of this research for human therapy have been discussed.

SELECTION OF CITATIONS
SEARCH DETAIL
...